Cargando…

Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes

PURPOSE: Early presentation of rejection facilitates early initiation of treatment which can favor a reversible rejection and better outcome. We analyzed the incidence, clinical features including rejection-treatment period and outcomes following graft rejection in our series of pediatric corneal gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusumesh, Rakhi, Vanathi, Murugesan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333541/
https://www.ncbi.nlm.nih.gov/pubmed/25709272
http://dx.doi.org/10.4103/0974-620X.149862
_version_ 1782358055617298432
author Kusumesh, Rakhi
Vanathi, Murugesan
author_facet Kusumesh, Rakhi
Vanathi, Murugesan
author_sort Kusumesh, Rakhi
collection PubMed
description PURPOSE: Early presentation of rejection facilitates early initiation of treatment which can favor a reversible rejection and better outcome. We analyzed the incidence, clinical features including rejection-treatment period and outcomes following graft rejection in our series of pediatric corneal graft. MATERIALS AND METHODS: Case records of pediatric penetrating keratoplasty (PK) were reviewed retrospectively, and parameters noted demographic profile, indication of surgery, surgery-rejection period, rejection-treatment interval, graft outcome, and complications. RESULTS: PK was performed in 66 eyes of 66 children <12 years, with an average follow-up of 21.12 ± 11.36 months (range 4-48 month). The median age at the time of surgery was 4.0 years (range 2 months to 12 years). Most of the children belonged to rural background. Scarring after keratitis (22, 33.4%) was the most common indication. Graft rejection occurred in eight eyes (12.12%) (acquired nontraumatic - 3, congenital hereditary endothelial dystrophy [CHED] - 2, nonCHED - 1, congenital glaucoma - 1, regraft - 1). The mean surgery-rejection period was 10.5 ± 7.3 months and mean rejection-treatment interval was 10.9 ± 7.02 days. CONCLUSION: This study showed irreversible graft rejection was the leading cause of graft failure of pediatric PK. Though, the incidence (12.1%) of graft rejection in current study was not high, but the percentage of reversal (25%) was one of the lowest in literature because of delayed presentation and longer interval between corneal graft rejection and treatment. In addition, categorization of the type of graft rejection was very difficult and cumbersome in pediatric patients.
format Online
Article
Text
id pubmed-4333541
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43335412015-02-23 Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes Kusumesh, Rakhi Vanathi, Murugesan Oman J Ophthalmol Original Article PURPOSE: Early presentation of rejection facilitates early initiation of treatment which can favor a reversible rejection and better outcome. We analyzed the incidence, clinical features including rejection-treatment period and outcomes following graft rejection in our series of pediatric corneal graft. MATERIALS AND METHODS: Case records of pediatric penetrating keratoplasty (PK) were reviewed retrospectively, and parameters noted demographic profile, indication of surgery, surgery-rejection period, rejection-treatment interval, graft outcome, and complications. RESULTS: PK was performed in 66 eyes of 66 children <12 years, with an average follow-up of 21.12 ± 11.36 months (range 4-48 month). The median age at the time of surgery was 4.0 years (range 2 months to 12 years). Most of the children belonged to rural background. Scarring after keratitis (22, 33.4%) was the most common indication. Graft rejection occurred in eight eyes (12.12%) (acquired nontraumatic - 3, congenital hereditary endothelial dystrophy [CHED] - 2, nonCHED - 1, congenital glaucoma - 1, regraft - 1). The mean surgery-rejection period was 10.5 ± 7.3 months and mean rejection-treatment interval was 10.9 ± 7.02 days. CONCLUSION: This study showed irreversible graft rejection was the leading cause of graft failure of pediatric PK. Though, the incidence (12.1%) of graft rejection in current study was not high, but the percentage of reversal (25%) was one of the lowest in literature because of delayed presentation and longer interval between corneal graft rejection and treatment. In addition, categorization of the type of graft rejection was very difficult and cumbersome in pediatric patients. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4333541/ /pubmed/25709272 http://dx.doi.org/10.4103/0974-620X.149862 Text en Copyright: © 2015 Kusumesh and Vanathi. http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Article
Kusumesh, Rakhi
Vanathi, Murugesan
Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes
title Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes
title_full Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes
title_fullStr Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes
title_full_unstemmed Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes
title_short Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes
title_sort graft rejection in pediatric penetrating keratoplasty: clinical features and outcomes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333541/
https://www.ncbi.nlm.nih.gov/pubmed/25709272
http://dx.doi.org/10.4103/0974-620X.149862
work_keys_str_mv AT kusumeshrakhi graftrejectioninpediatricpenetratingkeratoplastyclinicalfeaturesandoutcomes
AT vanathimurugesan graftrejectioninpediatricpenetratingkeratoplastyclinicalfeaturesandoutcomes